Company / SG&A Expense
IOVANCE BIOTHERAPEUTICS, INC. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$152.3M
FY2025
5-year range
$83.7M / $152.3M
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
#92 of 213
Health Care
What the data says
At $152M, IOVANCE BIOTHERAPEUTICS, INC.'s sg&a expense ranks #122 of 213 in the Health Care sector. SG&A Expense has increased for 9 consecutive years, from $8M in FY2016 to $152M in FY2025.
Based on SEC 10-K filings.
$152M in FY2025 with a 5-year CAGR of +20.4%.
Increased from $106M to $152M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +13.5%
- 5-Year CAGR
- +20.4%
- 10-Year CAGR
- -
Sector benchmark
#122 of 213 in Health CareTop 57% of 213This company $152.3M Sector average $722.3M
▼
-78.9% below sector average
Key checks
Key Insights
- IOVANCE BIOTHERAPEUTICS, INC.'s sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +20.4%, indicating consistent growth.
- In FY2025, sg&a expense increased 0.0% year-over-year.
- Ranks #92 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $152.3M | +0.0% |
| FY2024 | $152.3M | +43.5% |
| FY2023 | $106.1M | +1.9% |
| FY2022 | $104.1M | +24.4% |
| FY2021 | $83.7M | +39.0% |
| FY2020 | $60.2M | +47.4% |
| FY2019 | $40.8M | +43.7% |
| FY2018 | $28.4M | +33.7% |
| FY2017 | $21.3M | +159.5% |
| FY2016 | $8.2M | +113.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026